NCT04676360View on ClinicalTrials.gov

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

November 27, 2023

Study Completion Date

November 26, 2024

Conditions
Relapsed Plasmablastic LymphomaRefractory Plasmablastic LymphomaAnaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Interventions
DRUG

Belantamab Mafodotin

Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

02115

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Jacob Soumerai, MD

OTHER

NCT04676360 - Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter